Protecting Communities through effective Vector Control
Bayer initiates public dialogue on tackling vector borne diseases in India
New Delhi, September 26 2018: Rapid urbanization in India has led to a significant rise in Vector Borne Diseases (VBDs) such as Malaria, Dengue, Chikungunya, Filariasis, Japanese Encephalitis and Visceral Leishmaniasis. All these VBDs are preventable, what’s needed is effective and innovative vector control solutions and community education to spread awareness about disease prevention. To mobilize public-private collaboration on safeguarding public health and to pool industry know-how and resources, Bayer partnered with ASSOCHAM to organize a national dialogue on ‘Protecting Communities: Vector Control in Action’ at New Delhi today. The event was supported by the Niti Aayog; the National Vector Borne Disease Control Programme (NVBDCP), Ministry of Health and Family Welfare, Government of India and the New Delhi Municipal Council. Nearly 150 participants from key stakeholders such as the National Institute of Malaria Research (NIMR); the Indian Council for Medical Research (ICMR); World Health Organization (WHO), the Bill & Melinda Gates Foundation, Pest Control Operators, NGOs and local government officials attended the event. The common perception is that VBDs are diseases of marginalized communities, since they are endemic in low-income groups or in areas where the vicious cycle of diseases and poverty exists. However, with growth in Aedes borne diseases like Dengue and Chikungunya, nearly everyone is at risk irrespective of their income group. In addition to high mortality, VBDs put an economic burden on society through direct medical costs and indirect costs such as loss of productivity. In April 2018, Bayer signed ‘Zero by 40’, a global declaration that aims to eradicate Malaria by 2040 through the research, development and supply of innovative Vector Control solutions. In India, Bayer’s Environmental Science unit works closely with Public Health authorities, government organizations and industry associations to implement solutions for preventing VBDs. Bayer is also committed to support the Government of India’s national target for Malaria eradication by 2030 as part of the National Health Mission under the National Vector Borne Disease Control Programme (NVBDCP).
Speaking at the national dialogue on ‘Protecting Communities: Vector Control in Action’ at New Delhi, Dr. Arun Kumar, Head of Environmental Science at Bayer, South Asia, said: “Bayer strongly believes that challenges to public health are best tackled in collaboration with multiple stakeholders. Through today’s dialogue on Vector Control, we wanted to bring together industry experts to discuss prevention measures for Vector Borne Diseases.” Elaborating on Bayer’s role in Vector Control for India, Dr. Arun Kumar said: “Bayer will continue to collaborate with the Indian public health industry to tackle the rising incidence of diseases such as Malaria & Dengue. We will also continue to invest significantly into the research for innovative solutions to address resistance and other challenges in disease transmission. Improved vector control solutions will not only improve public health, it will also contribute to the United Nations' broader development agenda by addressing some of the key Sustainable Development Goals (SDGs) such as Good Health and Well-Being for People.” At the event, Bayer also introduced one of its new products for Vector Control: Aqua K-Othrine, which is soon to be launched in India. Aqua K-Othrine is India’s first water-based insecticide concentrate for application as a space spray adulticide in the management of mosquitoes. Aqua K-Othrine can be used in thermal fogging machines, ultra-low volume (ULV) sprayers and cold fogger machines.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.com
Find more information at: https://www.environmentalscience.bayer.in/Vector-ControlMedia Contact
Crop Science Communications, Bayer Group in India
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.